Limits...
Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.

Torres M, García-García L, Cruz-Hervert P, Guio H, Carranza C, Ferreyra-Reyes L, Canizales S, Molina S, Ferreira-Guerrero E, Téllez N, Montero-Campos R, Delgado-Sánchez G, Mongua-Rodriguez N, Sifuentes-Osornio J, Ponce-de Leon A, Sada E, Young DB, Wilkinson RJ - Eur. Respir. J. (2014)

Bottom Line: We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact.During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p⩽0.05).The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy.

View Article: PubMed Central - PubMed

Affiliation: Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.

No MeSH data available.


Related in: MedlinePlus

a) Interferon (IFN)-γ response to the pooled peptides assessed, comparing subjects with and without household contact with a patient with active tuberculosis (TB). b) Percentage of IFN-γ responders (>100 pg·mL−1) comparing subjects with and without household contact with a patient with active TB. c) IFN-γ response to tested antigens among contacts who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. d) Percentage of IFN-γ responders to the assessed antigens among subjects who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. No significant differences in the amount of IFN-γ production or the proportion of individuals responding to peptide pools was observed between documented and non-documented contacts. Among individuals whose isoniazid treatment was deferred, with the exception of CFP-10-2, there was no difference in IFN-γ secretion or the proportion of participants responding to peptide pools at the two different time-points. Tx: treatment; ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein; PPD: purified protein derivative.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4318657&req=5

Figure 2: a) Interferon (IFN)-γ response to the pooled peptides assessed, comparing subjects with and without household contact with a patient with active tuberculosis (TB). b) Percentage of IFN-γ responders (>100 pg·mL−1) comparing subjects with and without household contact with a patient with active TB. c) IFN-γ response to tested antigens among contacts who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. d) Percentage of IFN-γ responders to the assessed antigens among subjects who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. No significant differences in the amount of IFN-γ production or the proportion of individuals responding to peptide pools was observed between documented and non-documented contacts. Among individuals whose isoniazid treatment was deferred, with the exception of CFP-10-2, there was no difference in IFN-γ secretion or the proportion of participants responding to peptide pools at the two different time-points. Tx: treatment; ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein; PPD: purified protein derivative.

Mentions: No significant differences in the amount of baseline IFN-γ production (fig. 2a and online supplementary table S1) or the proportion of individuals (fig. 2b and table S1) responding to peptide pools was observed between documented and non-documented contacts. PBMCs from all contacts secreted detectable IFN-γ in response to almost all peptide pools and Rv1737 protein (fig. 2a). The strongest stimuli were peptide pools from Rv0849, Rv1986 and Rv1737 protein (fig. 2b and table S1). Among individuals whose isoniazid treatment was deferred, with the exception of CFP10-2, for which the IFN-γ response in samples drawn immediately before treatment were significantly higher, there was no difference in IFN-γ secretion (fig. 2c and table S2) or the proportion of participants (fig. 2d and table S2) responding to peptide pools at two different time-points before initiating therapy.


Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.

Torres M, García-García L, Cruz-Hervert P, Guio H, Carranza C, Ferreyra-Reyes L, Canizales S, Molina S, Ferreira-Guerrero E, Téllez N, Montero-Campos R, Delgado-Sánchez G, Mongua-Rodriguez N, Sifuentes-Osornio J, Ponce-de Leon A, Sada E, Young DB, Wilkinson RJ - Eur. Respir. J. (2014)

a) Interferon (IFN)-γ response to the pooled peptides assessed, comparing subjects with and without household contact with a patient with active tuberculosis (TB). b) Percentage of IFN-γ responders (>100 pg·mL−1) comparing subjects with and without household contact with a patient with active TB. c) IFN-γ response to tested antigens among contacts who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. d) Percentage of IFN-γ responders to the assessed antigens among subjects who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. No significant differences in the amount of IFN-γ production or the proportion of individuals responding to peptide pools was observed between documented and non-documented contacts. Among individuals whose isoniazid treatment was deferred, with the exception of CFP-10-2, there was no difference in IFN-γ secretion or the proportion of participants responding to peptide pools at the two different time-points. Tx: treatment; ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein; PPD: purified protein derivative.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4318657&req=5

Figure 2: a) Interferon (IFN)-γ response to the pooled peptides assessed, comparing subjects with and without household contact with a patient with active tuberculosis (TB). b) Percentage of IFN-γ responders (>100 pg·mL−1) comparing subjects with and without household contact with a patient with active TB. c) IFN-γ response to tested antigens among contacts who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. d) Percentage of IFN-γ responders to the assessed antigens among subjects who were assigned to deferred treatment, comparing the response 3 months before initiating treatment with that on treatment initiation. No significant differences in the amount of IFN-γ production or the proportion of individuals responding to peptide pools was observed between documented and non-documented contacts. Among individuals whose isoniazid treatment was deferred, with the exception of CFP-10-2, there was no difference in IFN-γ secretion or the proportion of participants responding to peptide pools at the two different time-points. Tx: treatment; ESAT-6: 6-kDa early secretory antigenic target; CFP-10: 10-kDa culture filtrate protein; PPD: purified protein derivative.
Mentions: No significant differences in the amount of baseline IFN-γ production (fig. 2a and online supplementary table S1) or the proportion of individuals (fig. 2b and table S1) responding to peptide pools was observed between documented and non-documented contacts. PBMCs from all contacts secreted detectable IFN-γ in response to almost all peptide pools and Rv1737 protein (fig. 2a). The strongest stimuli were peptide pools from Rv0849, Rv1986 and Rv1737 protein (fig. 2b and table S1). Among individuals whose isoniazid treatment was deferred, with the exception of CFP10-2, for which the IFN-γ response in samples drawn immediately before treatment were significantly higher, there was no difference in IFN-γ secretion (fig. 2c and table S2) or the proportion of participants (fig. 2d and table S2) responding to peptide pools at two different time-points before initiating therapy.

Bottom Line: We designed a two-group, two-arm, randomised clinical study of tuberculin skin test-positive participants: 26 with documented contact with TB patients and 34 with non-documented contact.During isoniazid therapy, a significant increase from baseline in the proportion of IFN-γ responders to the 10-kDa culture filtrate protein, Rv2031, Rv0849, Rv1986, Rv2659c, Rv2693c and the recombinant Rv1737 protein was observed (p⩽0.05).The peptide pool of Rv0849 and Rv1737 recombinant proteins induced the highest percentage of IFN-γ responders after isoniazid therapy.

View Article: PubMed Central - PubMed

Affiliation: Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.

No MeSH data available.


Related in: MedlinePlus